<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02824016</url>
  </required_header>
  <id_info>
    <org_study_id>2013-A00755-40</org_study_id>
    <secondary_id>2011-A00822-39</secondary_id>
    <secondary_id>2013-A00755-40</secondary_id>
    <nct_id>NCT02824016</nct_id>
  </id_info>
  <brief_title>Evaluation of Hypothyroidism Incidence After Breast Cancer Supraclavicular Irradiation</brief_title>
  <acronym>EPITHERM</acronym>
  <official_title>A Prospective Multicentric Evaluation of the Rate of Incidence of Hypothyroidism After Supraclavicular Irradiation for Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Jean-Godinot</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Jean-Godinot</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, multicentric, comparative, non randomised, in current care.&#xD;
&#xD;
      Primary objective:&#xD;
&#xD;
        -  To evaluate the incidence of hypothyroidism in breast cancer patients treated by&#xD;
           radiotherapy including the supra-clavicular area over a period of 5 years (60 months).&#xD;
&#xD;
      Secondary objectives :&#xD;
&#xD;
        -  To calculate the dose of irradiation received by thyroid gland during the treatment.&#xD;
&#xD;
        -  To compare the rate of incidence of hypothyroidism in women who received a&#xD;
           supra-clavicular irradiation (group 1)and in those who did not (group 2).&#xD;
&#xD;
        -  To estimate and compare the rate of incidence of chronic thyroid lesions in the 2&#xD;
           groups.&#xD;
&#xD;
        -  To look for predictive factors of hypothyroidism de novo in group 1 women particularly&#xD;
           regarding the dose-volume parameters.&#xD;
&#xD;
        -  To propose recommendations for the thyroid follow-up after supra-clavicular irradiation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, multicentric, comparative, non randomised, in current care study&#xD;
&#xD;
      2 patient groups, non randomised, according to the necessity or not to perform a&#xD;
      supra-clavicular irradiation:&#xD;
&#xD;
        -  Group 1 : patients receiving a supra-clavicular irradiation&#xD;
&#xD;
        -  Group 2 : patients not receiving a supra-clavicular irradiation.&#xD;
&#xD;
      Schedule&#xD;
&#xD;
      Projected inclusion duration of 18 months (duration to possibly adapt in order to obtain the&#xD;
      number of required patients)&#xD;
&#xD;
      Intermediate study of the results in 30 months&#xD;
&#xD;
      Duration of follow-up of 60 months&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">July 2020</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with treatment-related adverse effects on thyroid function as assessed by CTCAE v4.0</measure>
    <time_frame>Outcome measures will be assessed every 6 months up to 5 years.</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">500</enrollment>
  <condition>Irradiation; Adverse Effect</condition>
  <condition>Irradiation Hypothyroidism</condition>
  <arm_group>
    <arm_group_label>with supraclavicular irradiation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients received supraclavicular irradiation according to local policies. Biological samples were obtained in order to evaluate hypothyroidism during the follow-up period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>without supraclavicular irradiation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients did not receive supraclavicular irradiation according to local policies. Biological samples were obtained in order to evaluate hypothyroidism during the follow-up period</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>biological sample</intervention_name>
    <description>T4, thyrotropic-stimulating hormone (TSH) and Thyroglobulin antibody were systematically measured</description>
    <arm_group_label>with supraclavicular irradiation</arm_group_label>
    <arm_group_label>without supraclavicular irradiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>supraclavicular irradiation</intervention_name>
    <description>Irradiation of the homolateral supraclavicular area delivering 46 Gy in 23 fractions</description>
    <arm_group_label>with supraclavicular irradiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women older than 18&#xD;
&#xD;
          -  Non metastatic breast cancer, histologically proved, whatever T and N stages and&#xD;
             receptors status.&#xD;
&#xD;
          -  Breast cancer treated by surgery (either initial treatment then biotherapies and/or&#xD;
             neoadjuvant chemotherapy, either secondarily after biotherapies and/or neoadjuvant&#xD;
             chemotherapy, either without chemotherapy and/or biotherapies)&#xD;
&#xD;
          -  Breast cancer requiring an adjuvant radiotherapy&#xD;
&#xD;
          -  Treatment by radiotherapy made in participating centers&#xD;
&#xD;
          -  Information of patient and signature of the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pre-existent dysthyroidism revealed before radiotherapy or at inclusion checkup (THS&#xD;
             lower or superior to the standard of the laboratory, whatever the rate of free T4)&#xD;
&#xD;
          -  History of thyroid surgery&#xD;
&#xD;
          -  Bilateral breast cancer&#xD;
&#xD;
          -  History of cervical and/or supra-clavicular radiotherapy&#xD;
&#xD;
          -  Lack of social security insurance&#xD;
&#xD;
          -  Subjects deprived of free behavior or under administrative control&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yacine MERROUCHE, MD</last_name>
    <role>Study Director</role>
    <affiliation>Institut Jean-Godinot</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Jean Godinot</name>
      <address>
        <city>Reims</city>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie de Lorraine</name>
      <address>
        <city>Vandoeuvre-les-nancy</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 25, 2014</study_first_submitted>
  <study_first_submitted_qc>June 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2016</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institut Jean-Godinot</investigator_affiliation>
    <investigator_full_name>Tan Dat NGUYEN</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypothyroidism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

